Anemia clinical trials

Explore recruiting anemia clinical trials.

Recruiting anemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Anemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions.

Sweden, Hungary, Spain, Belgium, Czechia, Netherlands +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients with Alport Syndrome

Spain, Czechia, France, Austria, Lithuania, Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)

Spain, Italy, Greece, Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis.

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease

Germany, France, Italy, Spain, Greece

Phase II and Phase III (Integrated) EU CTIS Study details

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension

Hungary, Czechia, France, Greece, Netherlands, Poland +3 more

Phase II and Phase III (Integrated) EU CTIS Study details

Anemia trials by city

Anemia in Toronto Anemia in Vancouver Anemia in Montreal Anemia in Calgary Anemia in Edmonton Anemia in Ottawa Anemia in Winnipeg Anemia in Quebec City Anemia in Hamilton Anemia in Kitchener Anemia in London Anemia in Halifax Anemia in New York Anemia in Los Angeles Anemia in Chicago Anemia in Houston

Other conditions

Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease HIV Hepatitis B Hepatitis C COVID-19 Influenza RSV Sickle cell disease Hemophilia Thalassemia Chronic pain Low back pain Smoking cessation Tinnitus Hearing loss Chronic fatigue syndrome Obesity Type 2 diabetes Type 1 diabetes Prediabetes